参考文献/References:
[1]胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019, 34(3):209-220.
[2]Ikonomidis I,Kadoglou NN,Tritakis V,et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis,2014,234(1):34-41.
[3]Shi Y,Zhang P,Zhang LF,et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses[J]. Atherosclerosis,2007,191(1):54-62.
[4]Grallert H,Dupuis J,Bis JC,et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies[J]. Eur Heart J,2012,33(2):238-251.
[5]Zhuo SQ,Wolfert RL,Yuan C. Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A2 explain the discordance in results between the two assay methods[J]. Clin Biochem,2017,50(18):1209-1215.
[6]Topbas C,Swick A,Razavi M,et al. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between Elisa and activity assays[J]. Clin Chem,2018,64(4):697-704.
[7]Liu H,Rong P,Jia H,et al. A wash-free homogeneous colorimetric immunoassay method[J]. Theranostics,2016,6(1):54-64.
[8]Chen J,Zhang H,Chen W. Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation[J]. Clin Chim Acta,2019,488:143-149.
[9]张明明,于悦卿,赵培,等. 心肌梗死患者Lp-PLA2基因Y160X位点多态性检测的意义[J]. 东南大学学报（医学版）,2017,36(1):40-43.
[10]张明明,高伟,刘欣,等. 不同类型冠心病患者Lp-PLA2基因N133K位点多态性的意义[J]. 广东医学,2017,38(4):538-541.
[11]Zhang MM,Zhang CG,Yang CJ,et al. The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction[J]. Eur Rev Med Pharmacol Sci,2019,23(9):3960-3966.
[12]Wang Q,Hao Y,Mo X,et al.PLA2G7 gene polymorphisms and coronary heart disease risk:a meta-analysis[J].Thromb Res,2010,126(6):498-503.
[13]Jang Y,Waterworth D,Lee JE,et al. Carriage of the V279F null allele within the gene encoding Lp-PLA(2) is protective from coronary artery disease in South Korean males[J]. PLoS One,2011,6(4):e18208.
[14]Millwood IY,Bennett DA,Walters RG,et al. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults[J]. Int J Epidemiol,2016,45(5):1588-1599.
[15]Gregson JM,Freitag DF,Surendran P,et al. Genetic invalidation of Lp-PLA2 as a therapeutic target:large-scale study of five functional Lp-PLA2-lowering alleles[J]. Eur J Prev Cardiol,2017,24(5):492-504.
[16]孙旭,贾志,梁海青,等. 急性冠脉综合征患者血浆脂蛋白相关磷脂酶A2与GRACE积分的关系[J].山东医药,2015,55(8):43-45.
[17]李明. 血清Lp-PLA2、hs-CRP和D-二聚体在冠心病患者冠脉病变程度中的评估价值[J].重庆医学,2015,44(9):1215-1217.
[18]Ge PC,Chen ZH,Pan RY,et al. Synergistic effect of lipoprotein-associated phospholipase A2 with classical risk factors on coronary heart disease: a multi-ethnic study in China[J]. Cell Physiol Biochem,2016,40(5):953-968.
[19]Li J,Wang H,Tian J,et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J]. Medicine (Baltimore),2018,97(28):e11517.
[20]Yang L,Liu Y,Wang S,et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res,2017,45(1):159-169.
[21]Ma CY,Xu ZY,Wang SP,et al. Change of inflammatory factors in patients with acute coronary syndrome[J]. Chin Med J (Engl),2018,131(12):1444-1449.
[22]Li D,Wei W,Ran X,et al. Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population:a systematic review and meta-analysis[J]. Clin Chim Acta,2017,471:38-45.
[23]Benderly M,Sapir B,Kalter-Leibovici O,et al. Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease[J]. Biomarkers,2017,22(3-4):219-224.
[24]Dave M,Nash M,Young GC,et al. Disposition and metabolism of
darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in
humans[J]. Drug Metab Dispos,2014,42:415-430.
[25]Mohler ER,Ballantyne CM,Davidson MH,et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent:The results of a multicenter, randomized, double-blind, placebo-controlled study[J]. J Am Coll Cardiol,2008,51(17):1632-1641.
[26]Daida H,Iwase T,Yagi S,et al. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe[J]. Circ J,2013,77(6):1518-1525.
[27]Johnson JL,Shi Y,Snipes R,et al. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity:a randomized,controlled trial[J]. PLoS One,2014,9(2):e89034.
[28]O,Donoghue ML,Braunwald E,White HD,et al. Effect of darapladib on major coronary events after an acute coronary syndrome:The SOLID-TIMI 52 randomized clinical trial[J]. JAMA,2014,312(10):1006-1015.
[29]STABILITY Investigators,White HD,Held C,et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med,2014,370(18):1702-1711.
[30]Wallentin L,Held C,Armstrong PW,et al. Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease[J]. J Am Heart Assoc,2016,5(6): e003407
[31]高文君. 急性冠脉综合征预后的预测研究进展[J].心血管病学进展,2018,39(4):606-610.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(1):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(1):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[5]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[6]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[7]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(1):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[8]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(1):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[9]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(1):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[10]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]